MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

12 industry-sponsored trials across 6 sponsors

Showing 1 of 1 trial

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Merck	Aprepitant	Substance P/Neurokinin-1 Receptor Antagonist [EPC]	COMPLETED	2014-08-04	NCT01636947

Showing 4 of 4 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Charleston Laboratories, Inc	CL-108 5 mg	—	COMPLETED	2018-04-16	NCT03657810
Joseph Hazelton	CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)	—	COMPLETED	2015-07	NCT02462811
Charleston Laboratories, Inc	CL-108	—	COMPLETED	2015-01	NCT02462850
Charleston Laboratories, Inc	CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)	—	COMPLETED	2013-10	NCT01780428

Showing 6 of 6 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Eli Lilly	LY3537021	—	RECRUITING	2026-12	NCT07169851
Xiamen LP Pharmaceutical Co., Ltd	Palonosetron Hydrochloride Buccal Film 0.25 Mg	—	COMPLETED	2021-03-25	NCT04592198
Charleston Laboratories, Inc	Arm 1: CL-H1T	—	COMPLETED	2019-08-27	NCT03877718
Merck	Aprepitant	Substance P/Neurokinin-1 Receptor Antagonist [EPC]	COMPLETED	2016-09-26	NCT01732458
MonoSol Rx	Ondansetron (ODFS)	—	COMPLETED	2008-09-26	NCT01217190
Merck	Fosaprepitant dimeglumine	NK1R	TERMINATED	2013-12-06	NCT01405924

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Charleston Laboratories, Inc	CL-108	—	COMPLETED	2015-09	NCT02712554

Novel Drugs by Company (New molecular entities)

HELSINN HLTHCARE 1 drug

TERSERA 1 drug

ROLAPITANT HYDROCHLORIDE

CUMBERLAND 1 drug

Reformulations (10 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.